Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.72 |
| ▸ | TSHR | P16473 | 2/20 | 0.72 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.60 |
| ▸ | KIF11 | P52732 | 1/20 | 0.59 |
| ▸ | CSF1R | P07333 | 5/20 | 0.57 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539545 | 0.88 | MEN1 (0.63) | KMT2ATSHRMEN1RXFP1KIF11 | |
| SCHEMBL30041325 | 0.88 | MEN1 (0.63) | KMT2ATSHRMEN1RXFP1KIF11 | |
| SCHEMBL4928783 | 0.84 | KMT2A (0.69) | KMT2ATSHRMEN1RXFP1KIF11 | |
| SCHEMBL4928780 | 0.84 | KMT2A (0.69) | KMT2ATSHRMEN1RXFP1KIF11 | |
| SCHEMBL5178391 | 0.84 | MEN1 (1.00) | KMT2ATSHRMEN1RXFP1CSF1R | |
| SCHEMBL28216627 | 0.83 | MAPT (0.62) | KMT2AMEN1RXFP1MAPTLMNA | |
| SCHEMBL17777324 | 0.81 | KIF11 (0.63) | KMT2ATSHRMEN1RXFP1KIF11 | |
| SCHEMBL14214653 | 0.80 | GAA (0.57) | KMT2ATSHRMEN1KIF11BRAF | |
| SCHEMBL9191959 | 0.78 | KMT2A (0.71) | KMT2ATSHRMEN1KIF11CSF1R | |
| SCHEMBL13540540 | 0.78 | MEN1 (0.78) | KMT2ATSHRMEN1RXFP1CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008036643-A2 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | INCYTE CORPORATION (US) | 2008-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119491-A1 | AMIDINOHETEROCYCLES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE | IDO1, IDO2, INMT | KMT2A 1256/4885TSHR 1385/4885MEN1 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.